SML0150
Tolcapone
≥98% (HPLC), Catechol-O-methyltransferase inhibitor, powder
别名:
3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C14H11NO5
化学文摘社编号:
分子量:
273.24
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
产品名称
Tolcapone, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
yellow
solubility
DMSO: ≥15 mg/mL
originator
Roche
storage temp.
2-8°C
SMILES string
Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O
InChI
1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
InChI key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
Gene Information
human ... COMT(1312)
Application
Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.
Biochem/physiol Actions
Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Tolcapone
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable